Hypertrophic cardiomyopathy (HCM) is prevalent around the world, with a conservatively estimated 20 million individuals affected. Even in developed countries, current management of HCM is suboptimal. Much has been learned over the past 2 decades about the pathophysiology of HCM and new therapies such as mavacamten, CK-274, IMB-101, and CT-G20 are currently being developed and tested in clinical trials addressing the underlying pathophysiology of HCM. Although these new agents are in late stages of development, clinicians are often not fully up to date on this progress and the potential opportunity to improve care for patients.
Please join Drs. Maron and Rakowski in this final installment of a CMEO Snack series on HCM as they discuss methods to assess study results of emerging HCM disease-specific treatments targeting cardiac myosin in order to optimize outcomes for patients.
At the end of this CME/CE activity, participants should be able to assess study results of emerging HCM disease-specific treatments regarding cardiac myosin.
Supported by an educational grant from Bristol Myers Squibb.
Cardiologists, interventional cardiologists, electrophysiologists, cardiac surgeons (Secondary: Primary care physicians/General practitioners, PAs, nurse practitioners, nurses, and pharmacists)
Dr. Maron reports the following financial relationships:
Advisory Board: Cytokenetics (REDWOOD-HCM Steering Committee)
Consultant: Imbria and Takeda Pharmaceuticals U.S.A., Inc.
Dr. Rakowski has no financial relationships to disclose.
The following peer reviewer and CME Outfitters staff have no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).